Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.51 |
| ▸ | PREP | P48147 | 5/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | DHPS | P49366 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12581775 | 0.84 | PARP1 (0.48) | PARP1PREPHDAC4HDAC1HDAC6 | |
| SCHEMBL12582011 | 0.81 | PARP1 (0.45) | PARP1PREPHDAC4HDAC1HDAC6 | |
| SCHEMBL2022852 | 0.80 | PARP1 (0.63) | PARP1PREP | |
| SCHEMBL8272168 | 0.79 | PARP1 (0.38) | PARP1 | |
| SCHEMBL2022518 | 0.79 | ERCC1 (0.40) | PARP1PREPHDAC1HDAC6 | |
| SCHEMBL2026373 | 0.79 | PARP1 (0.41) | PARP1PREP | |
| SCHEMBL24879105 | 0.78 | PARP1 (0.53) | PARP1PREPHDAC4HDAC1HDAC6 | |
| SCHEMBL12581907 | 0.77 | PARP1 (0.52) | PARP1PREPHDAC4HDAC1HDAC6 | |
| SCHEMBL8271305 | 0.77 | PARP1 (0.49) | PARP1PREPHDAC4HDAC1HDAC6 | |
| SCHEMBL31409566 | 0.76 | HDAC1 (0.49) | PARP1PREPHDAC4HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968570-B2 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2011-06-28 | — | — | US | disclosed |
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | GRM1, GRIN1, GRM3 | PARP1 3945/4885PREP 3224/4885HDAC4 3609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.